Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

4D Molecular Therapeutics (FDMT) Gross Profit: 2020-2025

Historic Gross Profit for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Sep 2025 value amounting to $90,000.

  • 4D Molecular Therapeutics' Gross Profit rose 2900.00% to $90,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $120,000, marking a year-over-year increase of 605.88%. This contributed to the annual value of $37,000 for FY2024, which is 99.82% down from last year.
  • As of Q3 2025, 4D Molecular Therapeutics' Gross Profit stood at $90,000, which was up 500.00% from $15,000 recorded in Q2 2025.
  • Over the past 5 years, 4D Molecular Therapeutics' Gross Profit peaked at $20.2 million during Q3 2023, and registered a low of -$19,000 during Q4 2023.
  • Its 3-year average for Gross Profit is $1.9 million, with a median of $15,000 in 2025.
  • The largest annual percentage gain for 4D Molecular Therapeutics' Gross Profit in the last 5 years was 3,940.80% (2023), contrasted with its biggest fall of 101.52% (2023).
  • Over the past 5 years, 4D Molecular Therapeutics' Gross Profit (Quarterly) stood at $92,000 in 2021, then skyrocketed by 1,255.43% to $1.2 million in 2022, then slumped by 101.52% to -$19,000 in 2023, then skyrocketed by 105.26% to $1,000 in 2024, then surged by 2,900.00% to $90,000 in 2025.
  • Its Gross Profit was $90,000 in Q3 2025, compared to $15,000 in Q2 2025 and $14,000 in Q1 2025.